Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 13/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 13/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | PDE2A | O00408 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anagrelide SCHEMBL5060881 | 0.82 | PDE3B (1.00) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL9411 | 0.82 | PDE3B (1.00) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL29491059 | 0.82 | PDE3B (1.00) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL318593 | 0.81 | PDE3B (0.97) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL1449704 | 0.81 | PDE3B (0.97) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL9046734 | 0.81 | PDE3B (0.97) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL1568712 | 0.81 | PDE3B (0.97) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL729172 | 0.80 | PDE3B (0.94) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL16335881 | 0.77 | PDE3B (0.87) | PDE3BPDE3AMEN1PDE2AKMT2A | |
| Anagrelide SCHEMBL1664162 | 0.76 | PDE3B (0.85) | PDE3BPDE3AMEN1PDE2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022377-B2 | Method of treating hypertension | CIPLA LIMITED (IN) | 2018-07-17 | — | — | US | disclosed |
| US-20170157125-A1 | METHOD OF TREATING HYPERTENSION | CIPLA LTD. (IN) | 2017-06-08 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | PDE3B 2710/4885PDE3A 2969/4885MEN1 4733/4885 |
| US-10022377-B2 | Method of treating hypertension | AGT, CYP11B2, HMGCR | PDE3B 12/4885PDE3A 23/4885MEN1 1276/4885 |
| US-20170157125-A1 | METHOD OF TREATING HYPERTENSION | AGT, CYP11B2, HMGCR | PDE3B 12/4885PDE3A 23/4885MEN1 1276/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | PDE3B 4172/4885PDE3A 4397/4885MEN1 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.